68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Dec 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging tool called 68Ga-FAPI-Biotin, which is designed to help doctors see different types of cancer more clearly. The goal is to understand how safe this tool is, how it spreads in the body, and how much radiation it gives off. Researchers will compare the results from this new imaging method with other established methods to see how well it works in detecting tumors.
To participate in this trial, people generally need to have certain types of solid tumors and must provide written consent to join. Unfortunately, pregnant or breastfeeding women, as well as individuals with severe liver or kidney problems, cannot take part. Participants can expect to undergo imaging tests that use the new tool, and the study will help contribute to better cancer diagnostics in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Various solid tumors with available histopathological findings; Signed informed consent.
- Exclusion Criteria:
- • Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
About First Affiliated Hospital Of Fujian Medical University
The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Patients applied
Trial Officials
Weibing Miao, MD
Principal Investigator
First Affiliated Hospital of Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported